Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kids’ Cough/Cold Combos Need Label Comp, Actual Use Studies – AC Panel

This article was originally published in The Tan Sheet

Executive Summary

Recommendations by advisory committees could lead FDA to require label comprehension and actual use studies for multi-ingredient nonprescription cough/cold products for children

You may also be interested in...



U.K. Pulls Plug On Some Cough/Cold Products For Children Under 2

The U.K. health authority has withdrawn its authorization for some nonprescription cough and cold products to be used with children under 2 years old, with the products restricted from over-the-counter sales until additional instructions for use with 2- to 6-year-old children are added to their labels

U.K. Pulls Plug On Some Cough/Cold Products For Children Under 2

The U.K. health authority has withdrawn its authorization for some nonprescription cough and cold products to be used with children under 2 years old, with the products restricted from over-the-counter sales until additional instructions for use with 2- to 6-year-old children are added to their labels

U.K. Pulls Plug On Some Cough/Cold Products For Children Under 2

The U.K. health authority has withdrawn its authorization for some nonprescription cough and cold products to be used with children under 2 years old, with the products restricted from over-the-counter sales until additional instructions for use with 2- to 6-year-old children are added to their labels

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel